How Gline was paid
$163.3M in total for fiscal 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Matthew GlineChief Executive Officer | $725,000 | $4,978,875 | $157,577,851 | — | $12,018 | $163,293,744 |
| Richard PulikChief Financial Officer | $437,750 | $1,113,674 | $410,061 | $2,163,910 | $1,755 | $4,127,151 |
| Mayukh Sukhatme, M.D.President and Chief Investment Officer | $550,000 | $81,069,750 | $170,217,983 | — | $21,032 | $251,858,764 |
| Eric Venker, M.D.President and Immunovant CEO | $600,208 | $6,038,175 | $2,203,200 | $2,933,103 | $32,736 | $11,807,422 |
| Jennifer HumesChief Accounting Officer | $41,897 | $281,450 | $1,231,437 | $826,878 | $1,293 | $2,382,956 |
| Rakhi KumarFormer Chief Accounting Officer | $370,156 | $1,650,328 | $412,382 | $1,862,828 | $398,244 | $4,693,938 |
What changed and why
- $157.6M$157,577,851 in CEO stock awards drove Matthew Gline’s Fiscal 2024 total compensation to $163,293,744.
- $80.5M$80,550,000 retention award was approved for Mayukh Sukhatme, subject partly to repayment upon a Recoupment Event.
- 75%75% of Gline’s $5,725,000 total retention award vested and became payable in Fiscal 2024.
- $15.00$15.00 was the first share-price hurdle for Gline’s performance share units; no performance vesting occurred by fiscal year-end.
- 518:1 was the reported CEO-to-median-employee pay ratio, versus 2.3:1 using Fiscal 2023 compensation.
- 118:1 was the approximate ratio after annualizing Gline’s five-year RSU and PSU awards.
Other Roivant Sciences proxy statements
- 2026 proxy statement
Matthew Gline paid $3.1M, pay ratio 8.2:1.
Filed Jul 29, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.